Navigation Links
HOXB7 gene promotes tamoxifen resistance
Date:12/10/2010

A gene target for drug resistance, a triple-drug cocktail for triple negative breast cancer, and patients' risk for carpal tunnel syndrome are among study highlights scheduled to be presented by Johns Hopkins Kimmel Cancer Center scientists during the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12. The information is embargoed for the time of presentation at the symposium.

HOXB7 GENE PROMOTES TAMOXIFEN RESISTANCE
(Presentation # PD05-10)

Many postmenopausal women with early-stage breast cancers who initially respond well to tamoxifen become resistant to the drug over time and develop recurrent tumors. Johns Hopkins Kimmel Cancer Center researchers have found that a gene called HOXB7 may be the culprit in tamoxifen resistance.

Taken by mouth, tamoxifen is used at every stage of breast cancer to treat existing tumors and prevent new ones from developing. The drug works only in women whose tumor cells have a protein, called the estrogen receptor, which binds to the estrogen hormone. Tamoxifen binds to this estrogen receptor and blocks estrogen's effect on fueling cancer cells.

In experiments on cancer cells, the scientists found that when the HOXB7 gene is overexpressed, as occurs in many breast cancers, tumors cells became resistant to tamoxifen. Overexpression of HOXB7 results in proteins that interact with a series of other estrogen-activated genes and proteins, including the HER2 gene, known to make breast cancers aggressive. When the scientists knocked out the HOXB7 gene in one group of breast cancer cells, HER2 activation decreased and the cells became more responsive to tamoxifen. The scientists then showed how the HOXB7-HER2 interaction works.

"HOXB7 appears crucial in orchestrating estrogen receptors, HER2 and other receptors that promote aggressive tumor growth in breast cancer cells," says senior author Saraswati Sukumar, PhD, professor of oncology and co-director of the Breast Cancer Program at Johns Hopkins. "Dialing down expression of the HOXB7 gene could stave off tamoxifen resistance."

Though it's not yet evident how to shut down HOXB7, Sukumar says that oncologists could potentially use the drug Herceptin to kill tumors in patients whose HER2 expression increases.


'/>"/>

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. Difficult Dialogues Initiative promotes diversity at MU, around country
2. Gold Standard/Elsevier promotes medication safety and compliance via New MEDcounselor languages
3. New Anti-Aging Skin Care Line Promotes Penetration
4. Brain Health Expert Says OASIS Promotes Brain Fitness
5. Microfluidics Promotes Scientific University Research Using Nanotechnology with Innovation Incentives
6. Scientists find key to gene that promotes cancer metastasis
7. Scientific exchange program promotes collaborative quality standards for drugs, food ingredients
8. Pinstripe Promotes Jill Schwieters to President of Pinstripe Healthcare
9. Hearts and Minds Promotes Wellness; African Americans Living with Mental Illness Have Higher Risk for Other Illnesses.
10. Medical Transcription Services and EHR Provider MxSecure Promotes Tim Erkel to VP, Client Services
11. BioMed Realty Trust Promotes Matthew G. McDevitt to Executive Vice President, Real Estate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... IN (PRWEB) , ... June 20, 2017 , ... ... benefits advisory organization, announces recipients of its annual “UBBIE” Awards (pronounced you-bee) for ... who have demonstrated significant achievements toward their involvement with UBA, the clients they ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... services, has published a new eBook titled “ 5 Questions to Ask Before ... Research Analyst on the Genetic Test Evaluation (GTE) team, the book explores the ...
(Date:6/20/2017)... ... 2017 , ... EdChoice and the American Enterprise Institute each ... economic development in economically distressed urban areas. The first report presents a case ... the economic development of the city of Santa Ana, California. The second report ...
(Date:6/20/2017)... , ... June 20, 2017 , ... ... help content solutions for the enterprise, is proud to announce Touchpoints ... e-commerce, ticketing systems, company websites, and more to provide a seamless customer experience. ...
(Date:6/20/2017)... BC (PRWEB) , ... June 20, 2017 , ... As ... community on the link between stroke and gum disease. Those with bleeding gums in ... If left untreated, this condition can lead to heart disease, stroke and diabetes. Drs. ...
Breaking Medicine News(10 mins):
(Date:6/20/2017)... June 19, 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), will ... webcast on Friday, July 28, 2017, beginning at 7:30 a.m. ... Only Dial-in information: To participate in the conference call, dial ... the call at least 10 minutes prior to the start ... Webcast: A simultaneous ...
(Date:6/14/2017)... -- The Bio Supply Management Alliance (BSMA) has announced ... and the Biomedical Manufacturing Network to advance the ... California by providing a platform for imparting ... development. The primary focus of this alliance is to ... as small and mid-sized biomedical companies. ...
(Date:6/10/2017)... K. Burchfield, DPM, is recognized by Continental Who,s Who as a ... Alabama . Dr. Burchfield serves as ... over 20 years of experience, as well as expertise in the ... "The podiatry professional ... to welcome you to his practice," the company,s website states. "We ...
Breaking Medicine Technology: